Advertisement

Angel Biotechnology losses widen

Angel Biotechnology, which makes stem cells for medical research, posted wider half year losses as it looks to complete the joint venture agreement with MMH.

Angel Biotechnology, which makes stem cells for medical research, posted wider half year losses as it looks to complete the joint venture agreement with MMH.

Pre-tax loss widened to £2.86m for the six month period ended September 30th 2012 most of which is attributable to a write back of accrued revenue and contract liabilities related to joint ventures. Angel posted a loss of £241,000 the year before. Revenue for the period slipped to £1.07m from £1.4m previously.

Advertisement - Article continues below

The group, which has also suffered from client funding constraints, delays and cancellations, reported a loss per share of 0.08p compared to a loss of 0.009p previously.

Commercial Director and Acting CEO Dr Stewart White said: "The first half of 2012 has been a challenging period for Angel. The operational review of our business, measured against client requirements, has been thorough and has resulted in what we believe is the best outcome in the circumstances for our customers, staff and shareholders."

"The main outcome has been to progress the formation of the joint venture company with MMH, using our Pentlands facility, in addition to the proposed transfer of existing MMH contracts from Angel to the joint venture company."

The completion of the JV with MMH will reduce the group's cost base and will result in a lower fixed cost profile for the group and allow it to gradually scale up resources to match revenue opportunities, it explained.

"It is the aim of the board to provide a cash neutral H2 outturn at year end 2013 and to move towards positive free cash flow in 2013-14. At the same time, Angel is actively seeking strategic partnership opportunities for elements of its businesses to provide necessary contingencies and to convert market potential into earnings at an early stage," it said in a statement.

Shares in Angel Biotechnology plunged 16.47% at 0.7p at 09:00 in London.

CJ

Advertisement
Advertisement

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

How “support” and “resistance” can help you spot trading opportunities
Sponsored

How “support” and “resistance” can help you spot trading opportunities

Technical analysis can help traders manage risk and decide where to enter and exit a trade. One simple form of technical analysis is the concept of “s…
6 Jul 2020
House price crash: UK property prices are falling – so where next?
Property

House price crash: UK property prices are falling – so where next?

With UK property prices falling for the first time in eight years, are we about to see a house price crash? John Stepek looks at what’s behind the sli…
2 Jul 2020
A first-half home run for investment trusts
Sponsored

A first-half home run for investment trusts

The investment trust sector has seen some extraordinary performance in the first half of this year. Max King looks at what's behind it, and asks: is i…
7 Jul 2020